Cipla to make and sell Eli Lilly’s baricitinib to treat COVID-19
The Hindu
Cipla’s deal with Lilly expands the its portfolio of COVID-19 drugs.
Drugmaker Cipla Ltd said on Monday it had entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly’s arthritis drug baricitinib for the treatment of patients. The agreement comes at a time when India is struggling with a catastrophic second wave of the pandemic, leading to an acute shortage of coronavirus medicines such as remdesivir and tocilizumab. by Central Drugs Standard Control Organisation (CDSCO) for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen, Cipla said in a filing to stock exchanges.More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












